Description: Lung adenocarcinoma (LUAD) is the most common pathological subtype in NSCLC, accounting for approximately 55%. More than half of LUAD patients are older than 60 at diagnosis and about 30% of LUAD patients are over 70. Elderly LUAD patients usually do not tolerate surgery and are prone to heart disease, diabetes, and other primary diseases. Therefore, the selection of effective treatments with reduced toxicity and minimal side effects, well tolerated by geriatric patients, remains a critical clinical concern. With the development of precise diagnosis and treatment, more and more evidence suggests that targeted therapy guided by gene mutations has greatly improved treatment choices and survival benefits for NSCLC patients, including elderly LUAD patients. However, the results of LUAD driver gene mutation vary from region to region, patient to patient, lifestyle to lifestyle, and test methodologies. This study retrospectively analyzed mutations in 10 lung cancer-related driving genes in 275 elderly LUAD patients and explored their correlation with clinicopathological indicators such as gender, smoking status, tumor location, maximum diameter, lymph node metastasis and others.

Data type: Raw sequence reads

Sample scope: Multiisolate

Release date: 2023-05-25

Last updated: 2023-05-25

Data size: 133.74GB